By October 1, 2026: Billing team must update billing system to discontinue HCPCS code J3590 for Ponlimsi, denosumab-adet, Enoby/Xtrenbo, Osvyrti/Jubereq, Boncresa, and Oziltus. Add new HCPCS codes J1757 (effective 10/01/2026 for Avlayah), J9066 (effective 10/01/2026 for Avyxa bendamustine), and Q5173 (effective 10/01/2026 for Prolia biosimilars). Remove discontinued codes C9308 and J9999 from Kyxata billing. By November 10, 2026: Update prior authorization logic and clinical criteria in PA system for all 15+ affected medications (Avlayah, Bendamustine, Beovoumab, Bevacizumab Oncology, Cyramza, Denosumab, Elahere, Encelto, Halaven, Infliximab, Ixempra, Kyxata, Omalizumab, Paclitaxel Albumin-Bound, Pemetrexed, Pluvicto) to reflect NCCN guideline updates. Add new ICD-10 diagnosis codes (C83.36, C50.A0-C50.A2, D48.60-D48.62) to covered diagnosis tables. Update contractor information from National Government Services, Inc. to Wellpoint Federal in all systems and correspondence. Alert clinical staff and providers to new biosimilar products (Ponlimsi, denosumab-adet, Omlyclo, Avyxa) with parity status and steerage requirements. Update encounter forms and prior auth request templates to reflect simplified contraindication language (consolidated to 'member does not have FDA labeled contraindications'). Failure to implement code changes by October 1 will result in claim denials for new products and discontinued code rejections. Failure to update PA criteria by November 10 will cause inappropriate denials for compliant prescriptions.